Walgreens ducked compliance, filled fake opioid prescriptions, DOJ suit alleges
By 
Adrianne Appel2025-01-22T15:41:00
Walgreens skimped on compliance and filled millions of prescriptions for narcotics that weren’t medically necessary, the Department of Justice (DOJ) alleged in a complaint against the company, first brought by four whistleblowers.
The U.S. has been in the grip of a massive opioid addiction epidemic, fueled by prescription pain killers, primarily Oxycontin, the DOJ and states have alleged in dozens of lawsuits against opioid manufacturer Purdue Pharma and others.
The lawsuits allege the epidemic has been fueled by misinformation about the true addictiveness of the drugs, and the willingness of national pharmacy chains to forego compliance and dispense potentially fraudulent opioid prescriptions. Pharmacies are required under the Controlled Substances Act (CSA) to validate prescriptions for addictive drugs before filling them.
THIS IS MEMBERS-ONLY CONTENT
You are not logged in and do not have access to members-only content.
If you are already a registered user or a member, SIGN IN now.
Related articles
-
News BriefFTC case against insulin price gouging halted after commissioners fired by Trump
A Federal Trade Commission case against insulin price gouging has come to a screeching halt after two Democratic commissioners were fired by President Donald Trump.
-
PremiumPanelists break down robust sanctions landscape at TPRM Summit
Sanctions compliance officers face myriad challenges as complex geopolitical situations heighten risks worldwide, experts discussed during Compliance Week’s Third-Party Risk Management & Oversight Summit.
-
ArticleOpioid cases against retail pharmacy chains yield compliance lessons
Two cases involving five retail pharmacy chains winding their way through court foretell a long and costly road ahead for all companies across the pharmaceutical supply chain battling litigation for their alleged roles in fueling the opioid epidemic.
More from Regulatory Enforcement
-
News BriefSEC drops Morgan Stanley cash sweep case: Sign of the times?
A decision by the Securities and Exchange Commission to close an investigation into the cash sweep program at Morgan Stanley may affect decision-making at other financial institutions under similar scrutiny.
-
News BriefBuy now, pay later firms catch a break as CFPB backs off enforcement
The U.S. Consumer Financial Protection Bureau (CFPB) signaled a softer regulatory approach last month, easing its investigation of financial firms following the U.S. government’s broader efforts under President Donald Trump to scale back regulatory enforcement on businesses. The agency reaffirmed this pivot as it will ease scrutiny of “Buy Now, ...
-
News BriefUBS to pay $511 million fine over Credit Suisse tax case, exposing compliance gaps
A significant settlement in a U.S. tax fraud case against Credit Suisse contains numerous compliance lessons related to beneficial ownership and due diligence in mergers and acquisitions.